H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Evolus (EOLS – Research Report) today and set a price target of $27.00.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight Evolus’s potential for growth and market resilience. Despite a softer than expected first quarter, Evolus reported a significant increase in global net revenue and maintained its 2025 revenue guidance, indicating confidence in its growth trajectory. The company’s flagship product, Jeuveau, continues to gain market share, which helps cushion against broader market headwinds.
Additionally, Evolus’s strategic initiatives, such as the launch of Evolysse, are expected to contribute positively to sales, with early indicators showing strong customer interest and adoption. The company’s robust loyalty program and high reorder rates further underscore customer satisfaction and retention. Moreover, Evolus’s ability to navigate competitive dynamics, especially with leadership changes at market leader Allergan, positions it well for future success. These factors collectively support Tsao’s optimistic outlook and Buy rating for Evolus’s stock.
In another report released today, Mizuho Securities also maintained a Buy rating on the stock with a $25.00 price target.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EOLS in relation to earlier this year.